The strong Voyage data de-risks DT120 ODT's regulatory path in GAD and supports NDA submission. The next catalyst is the Panorama Phase 3 topline readout in GAD expected September 2026. Traders should monitor for that readout and any FDA regulatory updates, including potential rescheduling of lysergide.
Price Chart
Executive Summary
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD). The study met its primary endpoint (HAM-A change at Week 12) with a placebo-adjusted difference of -5.4 points (p<0.0001, Cohen's d=0.81) and all key secondary endpoints, with a safety profile consistent with prior studies. This is the second positive Phase 3 readout for DT120 ODT, supporting advancement toward an NDA submission and reinforcing the drug's potential to address a large unmet need in GAD.
Key Facts
- Phase 3 Voyage study met primary endpoint: HAM-A change at Week 12, placebo-adjusted -5.4 points (p<0.0001, Cohen's d=0.81)
- All key secondary endpoints met, including CGI-S at Week 12 and Day 2, and HAM-A at Week 1 (all p<0.0001)
- Response rate at Week 12: 43% DT120 vs 16% placebo (p<0.0001); remission rate: 14% vs 4% (p=0.0222)
- Safety profile consistent with prior studies; no new safety signals, no suicidality signal
- Second positive Phase 3 readout for DT120 ODT, following Emerge in MDD; Panorama GAD topline expected September 2026
Financial Impact
No financial data in filing; potential commercial opportunity for DT120 ODT in GAD and MDD, with company citing $2 billion revenue opportunity per 1% penetration of addressable market
Risk Factors
- Regulatory risk: FDA approval not guaranteed; DT120 contains a Schedule I substance requiring DEA rescheduling
- Competition from existing GAD treatments and other psychedelic drug developers
- Clinical trial risk for ongoing studies (Panorama, Ascend) and potential safety findings in larger populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094528 |
| Document: tm2622948d1_ex99-1.htm | 0001104659-26-094528 |
| Document: tm2622948d1_8k.htm | 0001104659-26-094528 |
| Document: 0001104659-26-094528-index-headers.html | 0001104659-26-094528 |
| Document: 0001104659-26-094528-index.html | 0001104659-26-094528 |
| Document: 0001104659-26-094528.txt | 0001104659-26-094528 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $40.25 $39.28 | ▼ −2.41% | ▼ −2.52% | $37.40 (−7.08%) |
Aug 12, 2026 7w ago | 8-K | $42.79 $45.82 | ▲ +7.08% | ▲ +7.53% | $37.40 (−12.60%) |
Aug 9, 2026 7w ago | Institutional Cluster | $45.15 $45.26 | ▲ +0.24% | ▲ +0.29% | $37.40 (−17.17%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 24, 2026 14w ago | 8-K | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 24, 2026 14w ago | 424B5 | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 22, 2026 14w ago | 424B5 | $36.18 $46.55 | ▼ −28.66% | ▼ −27.65% | $37.40 (−3.37%) |
Apr 27, 2026 22w ago | DEFA14A | $21.27 $21.75 | ▲ +2.26% | ▲ +0.56% | $37.40 (+75.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access